Trial Profile
A randomized, double blind placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of QBW251 in healthy subjects and multiple doses in cystic fibrosis patients
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Icenticaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Novartis
- 19 May 2021 Results of an analysis assessing the effect of the CFTR potentiator Icenticaftor (QBW251) on plasma Proteome in COPD patients with Chronic Bronchitis presented at the 117th International Conference of the American Thoracic Society
- 27 Jul 2020 This trial is completed in UK (Global End Date: 20 Nov 2015), according to European Clinical Trials Database record.
- 29 Feb 2016 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.